Eight versus four induction cycles of Carfilzomib, Thalidomide and Low-dose Dexamethasone: the Carthadex trial

被引：0

作者：

Wester, Ruth ^{[1
]}

Zweegman, Sonja ^{[2
]}

Van der Holt, Bronno ^{[3
]}

Jose, Kersten Marie ^{[4
]}

Vellenga, Edo ^{[5
]}

van Marwijk-Kooy, Marinus ^{[6
]}

Asselbergs, Emelie ^{[1
]}

de Weerdt, Okke ^{[7
]}

Minnema, Monique ^{[8
]}

Lonergan, Sarah ^{[9
]}

Palumbo, Antonio ^{[10
]}

Broijl, Annemiek ^{[1
]}

Sonneveld, Pieter ^{[1
]}

机构：

[1] Erasmus MC, Canc Inst, Rotterdam, Netherlands

[2] Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

[3] HOVON Data Ctr, Rotterdam, Netherlands

[4] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[5] Univ Med Ctr Groningen, Groningen, Netherlands

[6] Isala Clin, Zwolle, Netherlands

[7] St Antonius Hosp, Nieuwegein, Netherlands

[8] Univ Med Ctr Utrecht, Utrecht, Netherlands

[9] European Myeloma Network, Rotterdam, Netherlands

[10] Univ Turin, Azienda Osped Univ Citta Salute & Sci Torino, Turin, Italy

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

survival; Tolerability; treatment;

D O I：

10.1016/j.clml.2019.09.367

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SP-041

引用

页码：E220 / E221

页数：2